Sponsors (57)
The bill focuses federal attention, research, training, and targeted outreach to improve diagnosis, care, and equity for rare kidney diseases, but its modest or unspecified funding, implementation complexity, potential cost increases, privacy concerns from expanded genetic testing, and reporting delays limit and complicate how quickly and broadly benefits will be realized.
Patients with rare kidney diseases nationwide gain access to regional Centers, coordinated research (including genotype–phenotype studies), improved diagnostics, and potential new treatments that could delay or avoid dialysis and transplant.
People in underserved, rural, and disproportionately affected communities receive targeted outreach, screening, and recommendations to improve early diagnosis and slow disease progression, which may reduce disparities in kidney outcomes.
Health professionals gain expanded training, continuing education, and fellowship/stipend opportunities in nephrology and genetics, increasing workforce capacity to diagnose and manage rare kidney diseases.
Many provisions are authorized at relatively low or unspecified funding levels (e.g., $6M/year for Centers, unspecified fellowship funding), limiting the number, scale, and near‑term impact of programs.
Study and report recommendations (e.g., broader genetic testing, workforce expansion, coverage changes) could identify expensive actions that increase costs for Medicare/Medicaid beneficiaries and taxpayers if adopted.
Key reports and studies take 18–24 months (or are otherwise time‑limited), which may delay useful changes for patients now and/or produce preliminary results that miss longer‑term effects.
Based on analysis of 5 sections of legislative text.
Creates NIH-funded regional centers, HHS studies/experiments, and nephrology fellowship authority to improve research, detection, and treatment of rare kidney diseases; funds authorized for FY2026–2030.
Introduced February 24, 2025 by Gus Bilirakis · Last progress February 24, 2025
Creates a federal program to improve research, detection, prevention, and treatment of rare kidney diseases. It authorizes NIH grants to create regional Centers of Excellence, directs HHS to study testing and access issues and run experiments to find ways to delay or avoid dialysis/transplant, supports expanded nephrology training, and provides multi-year funding authorizations for these activities.